Scilex Holding Company(SCLX)Earnings, Financials & Key Ratios
SCLX•NASDAQ
$8.04
$56M mkt cap·Price updated May 7, 2026
AboutScilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.Show more
- Revenue$57M+21.1%
- EBITDA-$79M+21.7%
- Net Income-$73M+36.3%
- EPS (Diluted)-19.43+56.7%
- Gross Margin70.51%+6.1%
- EBITDA Margin-140.22%+35.3%
- Operating Margin-147.37%+34.7%
- Net Margin-128.66%+47.4%
- Interest Coverage-42.48+57.0%
SCLX Key Insights
Scilex Holding Company (SCLX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 34.2% free cash flow margin
✗Weaknesses
- ✗Shares diluted 86.7% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SCLX Price & Volume
Scilex Holding Company (SCLX) stock price & volume — 10-year historical chart
Loading chart...
SCLX Growth Metrics
Scilex Holding Company (SCLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years21.8%
TTM-26.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-328.32%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-25.64%
Return on Capital
10 Years-643.7%
5 Years-643.7%
3 Years-121.47%
Last Year-
SCLX Peer Comparison
Scilex Holding Company (SCLX) competitors in Specialty and biologics-focused pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PAHC | 1.75B | 43.16 | 36.27 | 27.37% | 6.29% | 30.81% | 2.67 | |
 HRMY | 1.82B | 31.42 | 11.59 | 21.51% | 16.2% | 17.19% | 0.28 | |
 PRGO | 1.61B | 11.72 | -1.14 | -2.75% | -43.5% | -50.65% | 1.35 | |
 SUPN | 3.01B | 52.28 | -76.88 | 8.63% | -3.74% | -2.73% | 0.04 | |
 COLL | 1.27B | 39.32 | 22.73 | 23.62% | 9.41% | 26.74% | 3.12 | |
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 PACB | 498.3M | 1.65 | -0.91 | 3.89% | -341.47% | -11.23% | 141.98 | |
 ACRS | 585.63M | 4.86 | -9.17 | -58.19% | -8.3% | -62.98% |
Compare SCLX vs Peers
Scilex Holding Company (SCLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SCLX Income Statement
Scilex Holding Company (SCLX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 23.56M | 31.32M | 38.03M | 46.74M | 56.59M | 40.36M |
| Revenue Growth % | - | 32.92% | 21.45% | 22.9% | 21.07% | -26.82% |
| Cost of Goods Sold | 2.15M | 3.63M | 10.8M | 15.68M | 16.69M | 12.68M |
| COGS % of Revenue | 9.12% | 11.6% | 28.39% | 33.55% | 29.49% | - |
| Gross Profit | 21.41M▲ 0% | 27.68M▲ 29.3% | 27.24M▼ 1.6% | 31.06M▲ 14.0% | 39.9M▲ 28.5% | 27.68M▲ 0% |
| Gross Margin % | 90.88% | 88.4% | 71.61% | 66.45% | 70.51% | 68.59% |
| Gross Profit Growth % | - | 29.29% | -1.61% | 14.04% | 28.46% | - |
| Operating Expenses | 56.67M | 63.52M | 77.87M | 136.49M | 123.3M | 290.98M |
| OpEx % of Revenue | 240.53% | 202.83% | 204.74% | 292.01% | 217.88% | - |
| Selling, General & Admin | 42.97M | 50.58M | 64.89M | 119.64M | 119.02M | 272.13M |
| SG&A % of Revenue | 182.39% | 161.52% | 170.62% | 255.95% | 210.31% | - |
| Research & Development | 9.96M | 9.2M | 9.05M | 12.75M | 9.64M | 14.72M |
| R&D % of Revenue | 42.28% | 29.38% | 23.8% | 27.27% | 17.04% | - |
| Other Operating Expenses | 3.74M | 3.74M | 3.92M | 4.11M | -5.36M | 4M |
| Operating Income | -35.26M▲ 0% | -35.84M▼ 1.6% | -50.63M▼ 41.3% | -105.43M▼ 108.2% | -83.4M▲ 20.9% | -263.3M▲ 0% |
| Operating Margin % | -149.65% | -114.44% | -133.13% | -225.55% | -147.37% | -652.37% |
| Operating Income Growth % | - | -1.65% | -41.29% | -108.22% | 20.9% | - |
| EBITDA | -31.48M | -32.06M | -46.18M | -101.28M | -79.35M | -259.25M |
| EBITDA Margin % | -133.62% | -102.37% | -121.42% | -216.68% | -140.22% | -642.36% |
| EBITDA Growth % | - | -1.84% | -44.05% | -119.32% | 21.66% | -274.2% |
| D&A (Non-Cash Add-back) | 3.78M | 3.78M | 4.45M | 4.15M | 4.05M | 4.04M |
| EBIT | -35.26M | -76.66M | -13.76M | -113.25M | -70.84M | -326.14M |
| Net Interest Income | -13.12M | -11.76M | -9.6M | -1.07M | -1.96M | -8.25M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 13.12M | 11.76M | 9.6M | 1.07M | 1.96M | 8.25M |
| Other Income/Expense | -12.31M | -52.58M | 27.27M | -8.89M | 10.59M | -71.09M |
| Pretax Income | -47.57M▲ 0% | -88.42M▼ 85.9% | -23.36M▲ 73.6% | -114.32M▼ 389.4% | -72.81M▲ 36.3% | -334.39M▲ 0% |
| Pretax Margin % | -201.92% | -282.34% | -61.42% | -244.57% | -128.66% | -828.52% |
| Income Tax | -53K | 5K | 4K | 13K | -1K | 17K |
| Effective Tax Rate % | 0.11% | -0.01% | -0.02% | -0.01% | 0% | -0.01% |
| Net Income | -47.52M▲ 0% | -88.42M▼ 86.1% | -23.36M▲ 73.6% | -114.33M▼ 389.3% | -72.81M▲ 36.3% | -375.83M▲ 0% |
| Net Margin % | -201.69% | -282.35% | -61.43% | -244.59% | -128.66% | -931.21% |
| Net Income Growth % | - | -86.08% | 73.58% | -389.35% | 36.32% | -328.32% |
| Net Income (Continuing) | -47.52M | -88.42M | -23.36M | -114.33M | -72.81M | -334.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | -2.78M |
| EPS (Diluted) | -0.01▲ 0% | -23.29▼ 184741.3% | -6.09▲ 73.9% | -44.85▼ 636.5% | -19.43▲ 56.7% | -32.39▲ 0% |
| EPS Growth % | - | -184741.27% | 73.85% | -636.45% | 56.68% | -25.64% |
| EPS (Basic) | -0.01 | -23.29 | -6.09 | -44.85 | -19.43 | - |
| Diluted Shares Outstanding | 4.03M | 3.8M | 3.83M | 3.72M | 6.95M | 11.6M |
| Basic Shares Outstanding | 4.03M | 3.8M | 3.83M | 3.72M | 6.95M | 11.6M |
| Dividend Payout Ratio | - | - | - | - | - | - |
SCLX Balance Sheet
Scilex Holding Company (SCLX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 22.42M | 23M | 29.61M | 46.78M | 41.55M | 16.49M |
| Cash & Short-Term Investments | 4.84M | 4.34M | 2.18M | 3.92M | 3.27M | 878K |
| Cash Only | 4.84M | 4.34M | 2.18M | 3.92M | 3.27M | 878K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 13.13M | 14.27M | 21.24M | 34.6M | 26.44M | 11.94M |
| Days Sales Outstanding | 203.35 | 166.29 | 203.79 | 270.16 | 170.55 | 148.7 |
| Inventory | 1.15M | 2.56M | 1.38M | 4.21M | 2.44M | 1.08M |
| Days Inventory Outstanding | 194.47 | 257.33 | 46.58 | 98.09 | 53.28 | 65.18 |
| Other Current Assets | 0 | 1.83M | 0 | 0 | 9.4M | 0 |
| Total Non-Current Assets | 59.08M | 54.93M | 56.92M | 54.53M | 51.41M | 259.39M |
| Property, Plant & Equipment | 2.52M | 2.11M | 1.9M | 3.67M | 2.93M | 2.39M |
| Fixed Asset Turnover | 9.35x | 14.86x | 19.99x | 12.75x | 19.29x | 15.16x |
| Goodwill | 13.48M | 13.48M | 13.48M | 13.48M | 13.48M | 13.48M |
| Intangible Assets | 42.54M | 38.8M | 40.59M | 36.48M | 32.45M | 30.42M |
| Long-Term Investments | 0 | 0 | 0 | 808K | 2.42M | 23.7M |
| Other Non-Current Assets | 538K | 538K | 944K | 89K | 119K | 197.11M |
| Total Assets | 81.5M▲ 0% | 77.93M▼ 4.4% | 86.53M▲ 11.0% | 101.31M▲ 17.1% | 92.95M▼ 8.2% | 275.88M▲ 0% |
| Asset Turnover | 0.29x | 0.40x | 0.44x | 0.46x | 0.61x | 0.30x |
| Asset Growth % | - | -4.38% | 11.03% | 17.08% | -8.25% | 133.12% |
| Total Current Liabilities | 78.48M | 169.42M | 44.84M | 250.38M | 259.63M | 358.95M |
| Accounts Payable | 8.12M | 4.28M | 8.45M | 40.95M | 52.62M | 67.36M |
| Days Payables Outstanding | 1.38K | 430.29 | 285.66 | 953.27 | 1.15K | 1.7K |
| Short-Term Debt | 28.9M | 58.06M | 0 | 108.43M | 34.88M | 54.51M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 8.89M |
| Other Current Liabilities | 26.66M | 103.34M | 264K | 491K | 169.04M | 417K |
| Current Ratio | 0.29x | 0.14x | 0.66x | 0.19x | 0.16x | 0.16x |
| Quick Ratio | 0.27x | 0.12x | 0.63x | 0.17x | 0.15x | 0.15x |
| Cash Conversion Cycle | -981.33 | -6.66 | -35.28 | -585.03 | -927.01 | -1.49K |
| Total Non-Current Liabilities | 144.71M | 132.39M | 5.45M | 23.87M | 25.96M | 96.65M |
| Long-Term Debt | 107.66M | 95.54M | 0 | 17.04M | 845K | 11.44M |
| Capital Lease Obligations | 1.65M | 1.15M | 665K | 2.24M | 1.52M | 4.89M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 35.4M | 30.51M | 4.78M | 4.59M | 20.91M | 138.26M |
| Total Liabilities | 223.19M | 301.81M | 50.29M | 274.25M | 285.59M | 455.6M |
| Total Debt | 138.63M | 154.75M | 1.41M | 128.46M | 37.96M | 67.67M |
| Net Debt | 133.79M | 150.41M | -774K | 124.54M | 34.69M | 66.79M |
| Debt / Equity | - | - | 0.04x | - | - | -0.38x |
| Debt / EBITDA | - | - | - | - | - | -0.26x |
| Net Debt / EBITDA | - | - | - | - | - | -0.26x |
| Interest Coverage | -2.69x | -3.05x | -5.27x | -98.72x | -42.48x | -39.55x |
| Total Equity | -141.68M▲ 0% | -223.88M▼ 58.0% | 36.24M▲ 116.2% | -172.94M▼ 577.2% | -192.64M▼ 11.4% | -179.72M▲ 0% |
| Equity Growth % | - | -58.01% | 116.19% | -577.22% | -11.39% | -23.85% |
| Book Value per Share | -35.15 | -58.98 | 9.45 | -46.46 | -27.71 | -15.49 |
| Total Shareholders' Equity | -141.68M | -223.88M | 36.24M | -172.94M | -192.64M | -176.94M |
| Common Stock | 20K | 13K | 14K | 16K | 24K | 1K |
| Retained Earnings | -264.13M | -352.55M | -375.91M | -490.25M | -563.05M | -888.67M |
| Treasury Stock | 0 | 0 | 0 | -90.52M | -90.52M | -76.92M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 6.32M | 3.35M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | -2.78M |
SCLX Cash Flow Statement
Scilex Holding Company (SCLX) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -31.46M | -28.66M | -21.26M | -20.71M | 19.35M | 19.35M |
| Operating CF Margin % | -133.54% | -91.53% | -55.89% | -44.3% | 34.19% | - |
| Operating CF Growth % | - | 8.89% | 25.84% | 2.59% | 193.44% | 377.2% |
| Net Income | -47.52M | -88.42M | -23.36M | -114.33M | -72.81M | -375.83M |
| Depreciation & Amortization | 3.78M | 3.78M | 3.96M | 4.15M | 4.05M | 4.04M |
| Stock-Based Compensation | 5.39M | 5.82M | 5.28M | 14.6M | 15.69M | 14.65M |
| Deferred Taxes | -800K | 12.76M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 623K | 23.79M | -52.8M | 9.08M | 7.58M | 329.59M |
| Working Capital Changes | 7.06M | 13.6M | 45.67M | 65.8M | 64.84M | 9.94M |
| Change in Receivables | -598K | -1.14M | -6.97M | -13.36M | -6.27M | 6.4M |
| Change in Inventory | 2.38M | -1.42M | 1.18M | -2.84M | 1.46M | 1.26M |
| Change in Payables | -4.06M | -3.84M | 2.81M | 19.88M | 7.42M | 16.51M |
| Cash from Investing | -25K | 0 | -2.07M | -330K | -2.67M | -895K |
| Capital Expenditures | -25K | 0 | -2.07M | -30K | -600K | -300K |
| CapEx % of Revenue | 0.11% | - | 5.43% | 0.06% | 1.06% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -300K | 0 | -8.57M |
| Cash from Financing | -19.17M | 28.16M | 21.17M | 23.58M | -18.13M | -30.16M |
| Debt Issued (Net) | -37.62M | -19.69M | -31.25M | 728K | -64.21M | -30.37M |
| Equity Issued (Net) | -93.21K | 0 | 96K | 1000K | 1000K | 1.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -10M | 0 | 0 |
| Other Financing | 18.54M | 47.85M | 52.33M | -2.6M | 1.44M | -19.3M |
| Net Change in Cash | -50.66M▲ 0% | -501K▲ 99.0% | -2.15M▼ 329.9% | 2.54M▲ 218.2% | -1.46M▼ 157.2% | -7.24M▲ 0% |
| Free Cash Flow | -31.49M▲ 0% | -28.66M▲ 9.0% | -23.32M▲ 18.6% | -21.04M▲ 9.8% | 19.35M▲ 192.0% | 23.82M▲ 0% |
| FCF Margin % | -133.64% | -91.53% | -61.33% | -45.01% | 34.19% | 59.02% |
| FCF Growth % | - | 8.96% | 18.63% | 9.81% | 191.98% | 122.66% |
| FCF per Share | -7.81 | -7.55 | -6.08 | -5.65 | 2.78 | 2.78 |
| FCF Conversion (FCF/Net Income) | 0.66x | 0.32x | 0.91x | 0.18x | -0.27x | -0.06x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
SCLX Key Ratios
Scilex Holding Company (SCLX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -64.47% | - | - | 180.51% |
| Return on Invested Capital (ROIC) | - | -107.08% | - | - | 120.05% |
| Gross Margin | 88.4% | 71.61% | 66.45% | 70.51% | 68.59% |
| Net Margin | -282.35% | -61.43% | -244.59% | -128.66% | -931.21% |
| Debt / Equity | - | 0.04x | - | - | -0.38x |
| Interest Coverage | -3.05x | -5.27x | -98.72x | -42.48x | -39.55x |
| FCF Conversion | 0.32x | 0.91x | 0.18x | -0.27x | -0.06x |
| Revenue Growth | 32.92% | 21.45% | 22.9% | 21.07% | -26.82% |
SCLX Frequently Asked Questions
Scilex Holding Company (SCLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Scilex Holding Company (SCLX) reported $40.4M in revenue for fiscal year 2024. This represents a 71% increase from $23.6M in 2020.
Scilex Holding Company (SCLX) grew revenue by 21.1% over the past year. This is strong growth.
Scilex Holding Company (SCLX) reported a net loss of $375.8M for fiscal year 2024.
Dividend & Returns
Scilex Holding Company (SCLX) generated $23.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More SCLX
Scilex Holding Company (SCLX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates